Stockreport

Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates

Xilio Therapeutics, Inc.  (XLO) 
PDF Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., [Read more]